secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001628280-24-045724
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q3 2024 revenue up 23% to $47.7M; guidance raised; net loss $5.3M
-----------------------------------------------------------------------

- Q3 total net product sales $47.7M (+23% YoY); Fanapt $23.9M (+12%), HETLIOZ $17.9M (+2%), PONVORY $5.9M (-32% QoQ).
- Net loss $5.3M vs net income $0.1M in Q3 2023; diluted EPS loss $0.09.
- Cash $376.3M; guidance raised: FY revenue $190-210M, year-end cash $370-390M.
- Fanapt bipolar I launch: new patient starts +90% Q3 2024 vs Q3 2023; Fanapt LAI Phase III starts Q4 2024.
- Milsaperidone NDA for schizophrenia/bipolar I expected early 2025; tradipitant NDA for motion sickness in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828024045724/0001628280-24-045724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828024045724/vnda-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer